CV Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 02:00 pm
Share
CV Sciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 2.65 million compared to USD 3.53 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago.
For the six months, net loss was USD 4.87 million compared to USD 6.66 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.05 compared to USD 0.06 a year ago.
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. Its hemp extracts, and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business to business-to-consumer. It operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based therapeutics. It develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under brands: +PlusCBD and Cultured Foods in the healthcare market sector: nutraceutical, beauty care, specialty foods, and pet products. +PlusCBD branded products are sold at select retail locations throughout the United States. Cultured Foods brand provides a variety of plant-based food products and caters to individuals seeking vegan, gluten-free, or flexitarian options for a culinary experience. It manufactures encapsulated softgels and tinctures for the supplement and nutrition industry.